Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06650833 in active rheumatoid arthritis with inadequate response to methotrexate
2016-002337-30Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zimlovisertib in rheumatoid arthritis (RA) (3 arms), sponsored by Pfizer. Primary endpoint: Change from baseline in SDAI. Started Jan 2017; status: completed.
02
Drugs
zimlovisertib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2016-002337-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002337-30.